VIDEM is accelerating the transitioning towards patient-centric care by enabling quick and accurate diagnostics of infectious diseases at the point of care, in your home or in the field.
We’re developing a small, handheld and low-cost molecular diagnostic device based on innovative
nucleic acid amplification and super sensitive, multiparametric readout. Our technology has been developed through state of the art chemistry, bio and nanotechnology. It’s universally applicable for all pathogens, enables multiplex testing and provides accurate test results in less than one hour, instead of days.
VIDEM is developed in collaboration with
A Swedish biotech company founded in 2021 by entrepreneurs and world leading scientists who share the passion and commitment to give people access to superior diagnostic solutions. We have gathered experience from publishing over hundreds of scientific papers, inventing methods, materials and products, and building companies.
We’re on a mission to improve the lives of many, prevent the spread of infections and antimicrobial resistance.
VIDEM won Almi Pitch 2022 at Åre Business Forum 2022.
VIDEM raises 5 MSEK in an initial pre-seed round for pioneering infectious disease diagnostics.
VIDEM is featured in Royal Swedish Academy (IVA) 100-list of research projects from Swedish universities that have potential to change the world.
We are looking for amazing people to join us on our journey towards improving detection of infections. This is an opportunity to join a startup in an early stage and work with groundbreaking technology to tackle one of our greatest global challenges.
Read more about current open full time positions below, and if you can’t find the role you are looking for, feel free to send an email to email@example.com!
© VIDEM AB 2022.